Regenerative expansion UK cosmetic regulatory registration completed for Cellav’s Regenativo+ enabling upcoming commercial launch in regenerative aesthetics and signaling readiness for broader international expansion, presenting a near-term cross-border sales opportunity in consumer-health and aesthetics markets.

US market entry Regenerative aesthetic products listed for US launch with two flagship products Regenativo+ and Placento+, positioning Pluri to target the large and growing US medical aesthetics market and accelerate sales channels through a US-friendly regulatory path.

3D cell platform Proprietary 3D cell-expansion technology offers scalable, cost-effective, batch-consistent cell production suitable for therapeutics, longevity, and agri-food tech, enabling partnerships with pharma, biotech, and food-tech players seeking mass cell production capabilities.

Collaborative leverage Existing collaborations with Remedy Cell and a network of ventures indicate a proven model for manufacturing and clinical-grade production, suggesting upsell opportunities in contract development, manufacturing, and co-development of additional cell-based solutions.

Global growth readiness Recent regulatory and product listings align with a strategy for international expansion, offering sales prospects across multiple regions, supported by a Nasdaq/TASE-listed biotechnology platform and a consumer-health aesthetics focus to diversify revenue streams.